Issue Date: June 1, 2009
Sanofi, Exelixis In Cancer Drug Pact
Sanofi-Aventis and Exelixis are teaming up to develop drugs that block phosphoinositide-3 kinase (PI3K), a protein implicated in tumor growth as well as in cancer cell survival and resistance to chemotherapy and radiation. Sanofi gains access to two PI3K inhibitors in early-stage clinical trials. In exchange, Exelixis scores a $140 million up-front payment and $21 million in research funding over the course of the three-year pact. The South San Francisco-based biotech firm says it could eventually see up to $1 billion in milestone and royalty payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society